Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

[1]  L. Cascione,et al.  The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.

[2]  F. Westermann,et al.  A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies , 2014, Oncogene.

[3]  A. Palumbo,et al.  5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies , 2014 .

[4]  P. Hérait,et al.  Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples , 2014 .

[5]  G. Inghirami,et al.  Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma , 2014 .

[6]  H. Dombret,et al.  Abstract LB-231: A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies , 2014 .

[7]  M. White-Koning,et al.  Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients , 2014, Investigational New Drugs.

[8]  J. Noel,et al.  Abstract C244: Development of the BET bromodomain inhibitor OTX015. , 2013 .

[9]  Travis J Cohoon,et al.  Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[10]  Reid C Thompson,et al.  Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.

[11]  J. Bradner,et al.  Small-molecule inhibition of BRD 4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia ( AML ) , 2013 .

[12]  J. Bradner,et al.  Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) , 2012, Oncotarget.

[13]  Ming-Ming Zhou,et al.  Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. , 2012, The Journal of Biological Chemistry.

[14]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[15]  Ming-Ming Zhou,et al.  Down-regulation of NF-κB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition* , 2012, The Journal of Biological Chemistry.

[16]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[17]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[18]  Marc Lavielle,et al.  Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..

[19]  Michel Struys,et al.  Pharmacokinetics in obese patients , 2004 .

[20]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  France Mentré,et al.  The Use of Population Pharmacokinetics in Drug Development , 1996, Clinical pharmacokinetics.

[22]  J. Wagner,et al.  History of pharmacokinetics. , 1981, Pharmacology & therapeutics.